SCHEMBL4886483

SCHEMBL4886483

O=C(O)C(O)c1ccccc1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
MAPK1 P28482 1/20 0.50
KMT2A Q03164 3/20 0.48
BCAT2 O15382 1/20 0.48
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
BCL2L1 Q07817 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HNF4A P41235 1/20 0.41
HDAC4 P56524 1/20 0.41
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
PPARA Q07869 3/20 0.40
PPARG P37231 2/20 0.40
FGFR1 P11362 1/20 0.40
FGFR2 P21802 1/20 0.40
FGFR4 P22455 1/20 0.40
FGFR3 P22607 1/20 0.40
MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8565449 0.87 KMT2A (0.42) LMNAMAPK1KMT2ABCAT2PPARA
SCHEMBL2395264 0.84 BCAT2 (0.55) LMNAMAPK1KMT2ABCAT2ALDH1A1
SCHEMBL2392699 0.84 BCAT2 (0.55) LMNAMAPK1KMT2ABCAT2ALDH1A1
SCHEMBL2395269 0.84 BCAT2 (0.55) LMNAMAPK1KMT2ABCAT2ALDH1A1
SCHEMBL28933159 0.83 LMNA (0.42) LMNAMAPK1KMT2ABCAT2ALDH1A1
SCHEMBL28962663 0.83 CES2 (0.42) LMNAMAPK1KMT2ABCAT2ALDH1A1
SCHEMBL9805372 0.82 LMNA (0.55) LMNAKMT2ABCAT2ALDH1A1HPGD
SCHEMBL1069525 0.82 PTGS2 (0.43) LMNAMAPK1KMT2APPARAPPARG
SCHEMBL275598 0.82 LMNA (0.64) LMNAMAPK1KMT2AALDH1A1HPGD
Hydrochloric Acid SCHEMBL11840084 0.82 PPARA (0.41) LMNAMAPK1KMT2ABCAT2PPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346553-A1 Process for the Preparation of R-Oxybutynin Hydrochloride HARMAN FINOCHEM LTD (IN) 2025-11-13 US disclosed
EP-4519242-A1 PROCESS FOR THE PREPARATION OF R-OXYBUTYNIN HYDROCHLORIDE Harman Finochem Limited (IN) 2025-03-12 EP disclosed
CN-118063305-A Method for synthesizing 2-cyclohexyl-2-hydroxyphenylacetic acid through continuous flow 深圳智微通科技有限公司 2024-05-24 CN disclosed
WO-2023214426-A1 PROCESS FOR THE PREPARATION OF R-OXYBUTYNIN HYDROCHLORIDE HARMAN FINOCHEM LIMITED (IN) 2023-11-09 WO disclosed
CN-110381934-A L-PAG derivatives for the treatment of Sleep Disordered Breathing (SDB) 芝加哥大学 2019-10-25 CN disclosed
US-20080058336-A1 Methods to Treat Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2008-03-06 US disclosed
US-20080058336-A1 Methods to Treat Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2008-03-06 US disclosed
US-20080058336-A1 Methods to Treat Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2008-03-06 US disclosed
US-7276484-B2 Dipeptide inhibitors of β-secretase ELAN PHARMACEUTICALS, INC. (US) 2007-10-02 US disclosed
US-7276484-B2 Dipeptide inhibitors of β-secretase ELAN PHARMACEUTICALS, INC. (US) 2007-10-02 US disclosed
WO-2000023414-A2 SYNTHESIS OF OPTICALLY ACTIVE CYCLOHEXYLPHENYLGLYCOLIC ACID AND ITS ESTERS SEPRACOR INC. (US) 2000-04-27 WO disclosed
US-6025177-A ENANTIOSELECTIVE SYNTHESIS OF CHIRAL ALPHA-HYDROXYCARBOXYLATE BY REACTING A PROCHIRAL ALPHA-KETOCARBOXYLIC ACID WITH A SINGLE ENANTIOMER OF AN N-SUBSTITUTED VICINAL AMINOALCOHOL OF SPECIFIC CYCLOHYDROCARBONS TO FORM ALPHA-HYDROXYCARBOXYLATE SEPRACOR INC. (US) 2000-02-15 US disclosed
US-6013830-A CHEMICAL INTERMEDIATES FOR OXYBUTYNIN, OXYPHENCYCLIMINE, OXYPHENONIUM BROMIDE, OXYPYRRONIUM BROMIDE, AND OXYSONIUM IODIDE, FOR WHICH CYCLOHEXYLPHENYLGLYCOLIC ACID (CHPGA) IS OF SPECIAL INTEREST; STEREOSELECTIVITY SEPRACOR INC. (US) 2000-01-11 US disclosed
US-5973182-A Carbonate Intermediates useful in the preparation of optically active cyclohexylphenylglycolate esters SEPRACOR INC. (US) 1999-10-26 US disclosed
WO-1999050205-A2 ASYMMETRIC GRIGNARD SYNTHESIS WITH CYCLIC 1,2 AMINOALCOHOLS SEPRACOR INC. (US) 1999-10-07 WO disclosed
EP-0746551-A1 OPTICALLY PURE 4-ARYL-2-HYDROXYTETRONIC ACIDS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 1996-12-11 EP disclosed
EP-0459455-B1 Process for producing optically active alpha-hydroxyesters CHISSO CORP (JP) 1996-09-04 EP disclosed
US-5248610-A Transesterification CHISSO CORPORATION (JP) 1993-09-28 US disclosed
EP-0459455-A2 Process for producing optically active alpha-hydroxyesters CHISSO CORPORATION (JP) 1991-12-04 EP disclosed
US-3941821-A ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETICS WILLIAM H. RORER, INC. (US) 1976-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346553-A1 Process for the Preparation of R-Oxybutynin Hydrochloride GCG, GRHPR, CYP8B1 LMNA 1055/4885MAPK1 2246/4885KMT2A 4794/4885
US-20080058336-A1 Methods to Treat Alzheimer's Disease PSEN2, PSEN1, ACHE LMNA 1749/4885MAPK1 4174/4885KMT2A 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.